Oral Vs Parentral Iron Therapy among Women in Post-Partum Period

Mamoona Suleman, Aneeza Akram, Jawariya Arooj


Objective:  To determine efficacy of oral iron therapy as compared to parentral iron therapy.

Study design and duration: This is a prospective study of observational type. Study consists on the duration of 5 months.

Setting: This study was conducted in Bahawal Victoria Hospital Bahawalpur.

Patients and Methods:  Anemic patients having Hb less than 10g/dl were included in this study. Two groups were formed group-A and group-B. Group-A was given oral iron therapy while group-B was given Intravenous iron therapy and outcome was noted after 30 days and 60 days in the form of hemoglobin level, hematochrit and MCV values. All data collected was analyzed using SPSS and Microsoft office version 2016. Results were calculated in the form of frequencies and percentages and averages. Tables and Graphs used to present data. Consent was taken from ethical committee of the study hospital and consent was also taken from all cases in study group.

Results:  There were total 70 cases in study group selected via randomized controlled trials. There were two groups containing 35 in each group. In group-A after 60 days of iron therapy via oral route HB value was 10.7 g/dl and after 60 days 11.8g/dl with the change of 22.4% in HB level. In Group-B after 60 days of intravenous iron therapy HB level was 12.9 g/dl with improvement of 38.8% in HB level. P- Value was 0.05. Age range of cases was 15-35 years of age with mean age of 31.4 years. Baseline characteristics of cases in group-A were age 33±4 years, BMI 23±5, HB level was 9.2±1 g/dl, Hematochrit (HCT) was 29.5±3 and MCV was 72±0.6. In group B mean age was 34±3, BMI 21±2, HB level 9.2±0.5, Hct was 28.6±3.4, MCV was 70±4.   

Conclusion:  Parentral route of iron therapy is more effective in post partum period in women than oral route with more improvement in blood hemoglobin, hematochrit and MCV value. 


iron therapy, Oral route, Parentral route, Hemoglobin, hematochrit, post partum period

Full Text:



Wojtyła C, Biliński P, Paprzycki P, Warzocha K.

Haematological parameters in postpartum women and their babies in Poland – comparison of urban and rural areas. Annals of Agricultural and Environmental Medicine 2011, Vol 18, No 2, 380-385

Bhagwan D, Kumar A, Rao CR, Kamath A. Prevalence of Anaemia among Postnatal Mothers in Coastal Karnataka. Journal of Clinical and Diagnostic Research. 2016 Jan, Vol-10(1).

Baker W. Iron deficiency in pregnancy, obstetrics and gynecology. Hematol Oncol Clin North Am 2000; 14:1061–77.

Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: Review of the literature. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 2003; 110:2-7.

Becuzzi N, Zimmermann R, Alexander Krafft A. Long-Term Efficacy of Postpartum Intravenous Iron

Therapy. BioMed Research International Vol 2014, 5 pages.

Trinh LTT, Dibley M. Anaemia in pregnant, postpartum and non-pregnant women in Lak district, Daklak province of Vietnam. Asia Pac J Clin Nutr, 2007; 16


Rathod S, Samal SK, Mahapatra PC, S. Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women. Int J Appl Basic Med Res. 2015 Jan-Apr; 5(1): 25–30.

Baig-Ansari N, Badruddin SH, Karmaliani R, Harris H, Jehan I, Pasha O, Moss N, McClure EM, Goldenberg.

Anemia prevalence and risk factors in pregnant women in an urban area of Pakistan. Food Nutr Bull. 2008 June; 29(2): 132–139.

Bodnar LM, Scanlon KS, Freedman DS, Siega-Riz AM, Cogswell ME. High prevalence of postpartum anemia among low-income women in the united states. American Journal of Obstetrics & Gynecology. 2001; 185:438-443.

World Heath Organization. Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World bank statement. Geneva: WHO; 1999.

Breymann C. Treatment of iron deficiency anaemia in pregnancy and postpartum with special focus on intravenous iron sucrose complex. Journal of the Medical Association of Thailand. 2005; 88:S108-9.

Rienold C, Dalenius K, Smith B, Brindley P, Grummer-Strawn L. Pregnancy nutrition surveillance 2007 report. Atlanta: U.S. Department of Health and Human Services, Center for Disease Control and Prevention; 2009.

Zainur RZ, Loh KY. Postpartum Morbidity - What We Can Do. Med J Malaysia, December 2006, Vol 61, No. 5.

Beard JL, Hendricks MK, Perez EM, et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. J Nutr. 2005; 135:267-272.

Rakesh PS, Gopichandran V, Jamkhandi D, Manjunath K, George K, Prasad J. Determinants of postpartum anemia among women from a rural population in southern India. International Journal of Women’s Health 2014:6 395–400.

Perez EM, Hendricks MK, Beard JL, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutr. 2005; 135:850-855.

Perello MF, Coloma JL, Masoller N, Esteve J, Palacio M. Intravenous ferrous sucose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia; a randomized controlled trial. BJOG, 2014; 121: 706-713.

Breymann C, Gliga F, Bejenariu C, Strizhova N.

Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. International Journal of Gynaecology & Obstetrics. 2008; 101:67-73.

Perewunsnyk G, Huch R, Huch A, et al. Parenteral iron therapy in obstetrics: 8 years experience with iron– sucrose complex. Br J Nutr. 2002; 88:3–10.

Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG. 2006; 113:1248–52.

Broche DE, Gay C, Armand-Branger S, et al. Severe anaemia in the immediate post-partum period. Clinical practice and value of intravenous iron. Eur J Obstet Gynecol Reprod Biol. 2005; 123(2):S21–7.

Geeta J, Urmila P, Jha SK. Intravenous Iron in Postpartum Anemia. The Journal of Obstetrics and Gynecology of India (January–February 2013) 63(1):45– 48.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.